Dr. John Axley M.D.

Recommended Articles

• Common Antioxidant May Slow Multiple Sclerosis Progression

  To date, multiple sclerosis (MS), a chronic neurological condition, affects more than 2.3 million individuals worldwide. The immune system mistakenly attacks the myelin, which is the protective layer that surrounds the nerve fibers. This, in turn, disrupts the regular nerve signaling between the...

• How an Understanding of Signaling Protein Can Help Treatment with Muscular Dystrophy

  Muscular dystrophy is a neuromuscular disease that takes on multiple forms. It is caused by a genetic mutation, which makes cells unable to produce the proteins necessary for muscular growth. In muscular dystrophy, the tissues eventually break down and cause progressive muscular weakness.This...

• Pregnancy and Parkinson’s Disease

  Parkinson's disease happens to only 5% of women before the age of 40, with less than 400 women who are younger than 50 years old diagnosed with the disease in the United States. This is why pregnancy in patients with Parkinson's Disease is uncommon and a rare occurrence.There have been previous...

• Holistic Treatment for Restless Legs Syndrome

  Restless legs syndrome is usually treated with lifestyle changes as well as medication. RLS causes people to experience unusual sensations in the legs while resting. These sensations can come in the form of:• Creepy-crawling feeling• Burning• Throbbing • PullingThese unpleasant feelings...

• What Are the Treatments for Cold Sores?

  Cold sores are inflamed fluid-filled blisters, which appear in clusters on and around the mouth or lips. They can be seen when a person has a weakened immune system during fever, cold, or any other disease. Usually, cold sores are not harmful and should heal on their own within two to four weeks...

• Nortis Inc. Receives $688K to Revolutionize Multiple Sclerosis Treatment

  One Seattle-based technology recently revealed new clinical technology that could completely change the way multiple sclerosis is treated. The firm received $668,000 to develop an in-vitro blood barrier that mimics the human blood-brain barrier, an innovation that would make MS drug development more...